Stockscreener 앱 받기
146.03
1.46%
-2.16
시장 영업 전:
143.62
-2.41
-1.65%
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer - GlobeNewswire Inc.
Novartis AG Stock Gains Traction on Analyst Upgrades and Oncology Pipeline Momentum in 2026 - AD HOC NEWS
Novartis AG stock dips on Swiss Exchange amid $3B breast cancer drug acquisition announcement - AD HOC NEWS
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug - Sahm
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline - ChartMill
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
NVS Stock Quote Price and Forecast - CNN
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrades and Pipeline Momentum - AD HOC NEWS
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrade and Portfolio Shifts - AD HOC NEWS
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Pharma Sector Shifts - AD HOC NEWS
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income - ChartMill
Novartis slides as shares trade ex-dividend for annual payout - Quiver Quantitative
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - Novartis
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis
Skeletal Dysplasia Market - GlobeNewswire Inc.
What's Driving the Market Sentiment Around Novartis AG? - Sahm
Novartis Stock: Can New Cancer Bets Keep Beating Big Pharma? - AD HOC NEWS
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas - Finviz
Avidity Biosciences shareholders approve merger with Novartis - Investing.com
Novartis stock hits all-time high at 167.87 USD - Investing.com
Novartis stock hits all-time high at 167.87 USD By Investing.com - Investing.com UK
Novartis India shares surge after Swiss parent agrees $159 mln exit deal - Investing.com India
Stocks To Watch, February 20: Swiggy, IT stocks, crude-sensitive stocks, Novartis India, ABB India, CIE Automotive, Zydus Life - Upstox
Where is Novartis AG (NVS) Headed? - Finviz
Nature - Novartis
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals - ChartMill
Itchy Skin Conditions? Novartis' Pivotal Trial Success Shows Potential For Targeted Relief - Sahm
A Look Into Novartis Inc's Price Over Earnings - Sahm
Novartis AG stock reaches all-time high at 160.21 USD - Investing.com Nigeria
Novartis AG stock reaches all-time high at 160.21 USD By Investing.com - Investing.com South Africa
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
IgA Nephropathy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - Barchart.com
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com Nigeria
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Sahm
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Novartis stock hits all-time high at 153.83 USD By Investing.com - Investing.com Australia
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales - Finviz
Novartis stock hits all-time high at 153.83 USD - Investing.com
Earnings call transcript: Novartis Q4 2025 earnings beat forecasts, stock jumps - Investing.com
0.02%
자본화:
|
볼륨(24시간):